In July 2024, Checkpoint announced that the FDA accepted for review the resubmission of its BLA for cosibelimab as a complete ...

Repligen sees FY24 adjusted EPS $1.50-$1.58, consensus $1.43 Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

Beauty of cosmic proportions found in microscopic imaging WALTHAM, Mass., Nov. 12, 2024 () – Evident unveiled the ...

WALTHAM, Mass., November 12, 2024--(BUSINESS WIRE)--Dynatrace (NYSE: DT) today announced that its executives will present at ...

WALTHAM, Mass. and BOULDER, Colo., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases ...

Third quarter reported revenue of $155 million, an increase of 10% year-over-yearCDMO revenue and orders both up ~20% year-over-yearOverall order ...

WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for ...

Repligen Corporation, established in 1981 and headquartered in Waltham, Massachusetts, is a global life sciences company ...

INDIGO is the largest clinical trial conducted in patients living with IgG4-RD- -Topline INDIGO results expected by the end ...

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Repligen Corp. (RGEN) on Tuesday reported a loss of $653,000 in its third quarter. On a per-share basis, the Waltham, Massachusetts-based company said it ...